ARROWHEAD RESEARCH (HDP1 BE) stock market data APIs
€58.7591
0(0%)
as of December 23, 2025
Try our APIs with
free plan!
ARROWHEAD RESEARCH Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for HDP1.BE.
Prev. Close
58.7591
Open
58.7591
High
58.7591
Low
58.7591
52 wk Range
8.77-60.02
Market Cap
6 485 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get ARROWHEAD RESEARCH data using free add-ons & libraries
Get ARROWHEAD RESEARCH Fundamental Data
ARROWHEAD RESEARCH Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-25
- EPS/Forecast: -0.16
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ARROWHEAD RESEARCH News
New
Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events
PASADENA, Calif., December 23, 2025--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Obesity KOL ...
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
PASADENA, Calif., December 15, 2025--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on December 12,...
Arrowhead price target raised to $80 from $52 at RBC Capital
RBC Capital raised the firm’s price target on Arrowhead (ARWR) to $80 from $52 and keeps an Outperform rating on the shares after meeting with its management team. The recent approval of Redemplo ma...
Arrowhead Pharmaceuticals (ARWR) Valuation Check as ARO-MAPT Enters First Human Trial in Alzheimer’s Treatment
Arrowhead Pharmaceuticals (ARWR) just started dosing patients in its Phase 1/2a trial for ARO-MAPT, an RNA interference therapy aimed at tauopathies like Alzheimer’s, and the stock has been reacting...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
